Table 3. Immunohistochemistry results for β-catenin, map2 and synaptophysin analysed on CNS PNET and pineoblastoma cohorts.
Tumour type | Primary/recurrence | β-Catenin | MAP2 | Synaptophysin |
---|---|---|---|---|
CNS PNET |
Primary |
Negative |
Negative |
Negative |
CNS PNET |
Primary |
Negative |
High positive |
Positive |
CNS PNET |
Primary |
Negative |
High positive |
Negative |
CNS PNET |
Primary |
Negative |
|
Positive |
CNS PNET |
Primary |
Negative |
|
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Negative |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Low positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
Low positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
Low positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Low positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Negative |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
Negative |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Negative |
Positive |
CNS PNET |
Primary |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Primary |
Cytoplasmic |
Low positive |
|
CNS PNET |
Primary |
Cytoplasmic |
|
Positive |
CNS PNET |
Primary |
Cytoplasmic |
|
Positive |
CNS PNET |
Primary |
Cytoplasmic |
|
Negative |
CNS PNET |
Primary |
Cytoplasmic |
|
Negative |
CNS PNET |
Primary |
Cytoplasmic |
|
Negative |
CNS PNET |
Primary |
Low nuclear |
Negative |
Positive |
CNS PNET |
Primary |
Low nuclear |
High positive |
Negative |
CNS PNET |
Primary |
Low nuclear |
High positive |
Positive |
CNS PNET |
Primary |
High nuclear |
Negative |
Negative |
CNS PNET |
Primary |
High nuclear |
Negative |
Negative |
CNS PNET |
Primary |
High nuclear |
Negative |
Negative |
CNS PNET |
Primary |
High nuclear |
Low positive |
Negative |
CNS PNET |
Primary |
High nuclear |
Low positive |
Positive |
CNS PNET |
Primary |
High nuclear |
Low positive |
Negative |
CNS PNET |
Primary |
High nuclear |
|
Positive |
CNS PNET |
Recurrence |
Cytoplasmic |
High positive |
Negative |
CNS PNET |
Recurrence |
Cytoplasmic |
High positive |
Positive |
CNS PNET |
Recurrence |
Low nuclear |
|
Positive |
CNS PNET |
Recurrence |
High nuclear |
Low positive |
Negative |
CNS PNET |
Recurrence |
High nuclear |
Negative |
Negative |
CNS PNET |
Recurrence |
High nuclear |
|
Positive |
Pineoblastoma |
Primary |
Negative |
Low positive |
Positive |
Pineoblastoma |
Primary |
Negative |
High positive |
Positive |
Pineoblastoma |
Primary |
Cytoplasmic |
Low positive |
Positive |
Pineoblastoma |
Primary |
Cytoplasmic |
High positive |
Positive |
Pineoblastoma |
Primary |
Cytoplasmic |
|
Positive |
Pineoblastoma |
Primary |
Cytoplasmic |
|
Positive |
Pineoblastoma |
Primary |
Low nuclear |
Low positive |
Negative |
Pineoblastoma | Primary | Low nuclear | Positive |
Abbreviation: CNS PNET=central nervous system primitive neuroectodermal tumour.